Gemcitabine

製品コードS1714 別名：LY-188011, NSC 613327

Gemcitabine 化学構造

分子量(MW)：263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

サイズ 価格(税別)  
JPY 21580.00
JPY 16102.00
お問い合わせ バルク問合せ

文献中Selleckの製品使用例(18)

カスタマーフィードバック(4)

  • RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

    Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
体外試験

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1yxO2lEPTB;MD6wNFA1PThibl2= M4fIWnNCVkeHUh?=
ES4 M3rMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\1fYZ2UUN3ME2wMlAxODZ3MzDuUS=> NVTzbHJMW0GQR1XS
ACHN M1;kXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMECwPFg4KG6P MXTTRW5ITVJ?
KYSE-510 MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;hNnZLUUN3ME2wMlAxODl5NTDuUS=> M1m3RXNCVkeHUh?=
EW-7 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHEOZlHUUN3ME2wMlAxOjV6IH7N MUDTRW5ITVJ?
BFTC-905 NXvnXFBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMEC1NVUhdk1? NVKzeHNmW0GQR1XS
KE-37 MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojXTWM2OD1yLkCwOVYyKG6P NUPIR|dQW0GQR1XS
SBC-5 M1rxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMEC1O{BvVQ>? NUXDXIpTW0GQR1XS
NKM-1 M2HVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\QTWM2OD1yLkCwO|A6KG6P NVfib|BJW0GQR1XS
RH-1 NIDW[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIf4ZmVKSzVyPUCuNFA4OThibl2= MYfTRW5ITVJ?
ALL-PO NXK3WnlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLmTWM2OD1yLkCwPFMhdk1? MXXTRW5ITVJ?
QIMR-WIL NUn0ZVJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPTN2dKSzVyPUCuNFA5QTRibl2= NYjNNItvW0GQR1XS
A375 Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vu[WlEPTB;MD6wNFk6PSCwTR?= M4LqV3NCVkeHUh?=
SIG-M5 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjiUlFKSzVyPUCuNFExPCCwTR?= NV34R2xHW0GQR1XS
KGN NI\JXJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMEGwPEBvVQ>? NHrTXohUSU6JRWK=
EW-13 NHXpUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPzUoNKSzVyPUCuNFEyOiCwTR?= M4TwdXNCVkeHUh?=
NCI-SNU-1 Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DOUGlEPTB;MD6wNVYhdk1? NFjBVW9USU6JRWK=
PSN1 NXjvRpdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMEG2OUBvVQ>? NFuyTW1USU6JRWK=
HUTU-80 NFWycVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF32eZJKSzVyPUCuNFE3PiCwTR?= MVLTRW5ITVJ?
EW-16 NHXENYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1f0[GlEPTB;MD6wNlMhdk1? MV3TRW5ITVJ?
786-0 NH:5fnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILuNnNKSzVyPUCuNFI{KG6P M{\XWHNCVkeHUh?=
ES1 NIC2VolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe3NG1KSzVyPUCuNFI3QCCwTR?= M{HjdnNCVkeHUh?=
RKO MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzVfphKSzVyPUCuNFI4QSCwTR?= NUDRRZQ5W0GQR1XS
ESS-1 Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPveWJvUUN3ME2wMlAzQDZibl2= M1jJUHNCVkeHUh?=
SK-UT-1 Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVezV41bUUN3ME2wMlAzQTdibl2= MmDzV2FPT0WU
LB2241-RCC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMEOxPEBvVQ>? MXvTRW5ITVJ?
CHL-1 NX:zTlZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3ETWM2OD1yLkCzNlQhdk1? NGTXXZRUSU6JRWK=
SW1783 MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLpTWM2OD1yLkCzN|Yhdk1? NVSwcJVoW0GQR1XS
MEL-JUSO M2rkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPRdJBKSzVyPUCuNFM6OSCwTR?= NGeweoNUSU6JRWK=
HT-29 NWTId|IxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMESxN{BvVQ>? NUnLd|VFW0GQR1XS
SNG-M NI\2O49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYezOmFEUUN3ME2wMlA1OjVibl2= NYDsToJqW0GQR1XS
TE-15 M1rNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrXcYJyUUN3ME2wMlA1PjRibl2= NVT5eGFtW0GQR1XS
HOS M3zkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMES4JI5O M2nu[nNCVkeHUh?=
BB65-RCC NVTSXm9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS5bpE6UUN3ME2wMlA2OTJibl2= NWr1XIljW0GQR1XS
HCE-4 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fjT2lEPTB;MD6wOVI5KG6P NEjmSmhUSU6JRWK=
MHH-ES-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3hTWM2OD1yLkC1N|Ehdk1? NVHHRZN2W0GQR1XS
RPMI-7951 NGLmPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULDTmVXUUN3ME2wMlA2PDFibl2= MXTTRW5ITVJ?
IST-SL2 NWHkeYtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DUXGlEPTB;MD6wOVg1KG6P M1HQRnNCVkeHUh?=
CMK M3rZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMEW4OkBvVQ>? NIPFc4JUSU6JRWK=
GR-ST M{\oXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMEW5OUBvVQ>? Mn;KV2FPT0WU
NALM-6 NY\Wc3pRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\QbXJXUUN3ME2wMlA3OjJibl2= MULTRW5ITVJ?
RPMI-6666 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrZ[ppYUUN3ME2wMlA3PTJibl2= MlLaV2FPT0WU
LC-2-ad M4HwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm4OotXUUN3ME2wMlA3PTNibl2= MmTHV2FPT0WU
ARH-77 NX;LUYxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3mOY9KSzVyPUCuNFcyOSCwTR?= NUnJfFUyW0GQR1XS
IST-MEL1 MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMEeyOkBvVQ>? NFv6PHhUSU6JRWK=
SW1710 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD2O5VkUUN3ME2wMlA4PTFibl2= MXrTRW5ITVJ?
DEL NInmeIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnYUVNpUUN3ME2wMlA5QDdibl2= NH7KZ|dUSU6JRWK=
AGS MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3yxdWlEPTB;MD6wPVAzKG6P Mn\OV2FPT0WU
NCI-H2122 NUDoPHV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEm0OkBvVQ>? NHzYdJNUSU6JRWK=
HSC-4 M{PhRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELaNndKSzVyPUCuNVAzKG6P MWHTRW5ITVJ?
AM-38 NY\RSXhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfTOINDUUN3ME2wMlEzOSCwTR?= Mme2V2FPT0WU
769-P NEm5ZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HqUWlEPTB;MD6xNlMhdk1? M1PDTXNCVkeHUh?=
RT-112 MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\YTWM2OD1yLkGyO{BvVQ>? NVPLbXZqW0GQR1XS
MCF7 M3HONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjjPXpKSzVyPUCuNVM3KG6P M4TyR3NCVkeHUh?=
IGROV-1 NUfFR25WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33yZmlEPTB;MD6xOFUhdk1? MV\TRW5ITVJ?
OCI-AML2 MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrZTWM2OD1yLkG0O{BvVQ>? MV7TRW5ITVJ?
NCI-H1299 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTuWo03UUN3ME2wMlE2PyCwTR?= M3L3b3NCVkeHUh?=
A431 MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEO4SZpKSzVyPUCuNVg{KG6P M2jpeXNCVkeHUh?=
SW982 NXvXXHhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPLcmJXUUN3ME2wMlIyOyCwTR?= NYi5TW9UW0GQR1XS
BB30-HNC NVfn[mRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3mTWM2OD1yLkKzNUBvVQ>? MnviV2FPT0WU
ACN NGH1VVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi3RotiUUN3ME2wMlI1PCCwTR?= NH\w[|BUSU6JRWK=
647-V M17TNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzySmlKSzVyPUCuNlQ5KG6P MVnTRW5ITVJ?
SK-PN-DW NXfoWFFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfwTWM2OD1yLkK2OkBvVQ>? M1LUU3NCVkeHUh?=
LCLC-97TM1 NYHy[mxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHaeFNsUUN3ME2wMlI3PyCwTR?= NGK1fXpUSU6JRWK=
LB1047-RCC NEDCNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L2OWlEPTB;MD6yOlkhdk1? NIntdZFUSU6JRWK=
A2780 NFTsZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4C4XWlEPTB;MD6yO{BvVQ>? M4r5bXNCVkeHUh?=
C-33-A MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnnS2pKSzVyPUCuNlc{KG6P M{TBOHNCVkeHUh?=
NCI-H2228 NEXVSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrDTWM2OD1yLkOxOEBvVQ>? M2\xe3NCVkeHUh?=
TE-5 MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwM{G2JI5O NHzEdXhUSU6JRWK=
HC-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjxTWM2OD1yLkOyO{BvVQ>? MknrV2FPT0WU
SK-MES-1 M1Sxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvzTWM2OD1yLkOyPEBvVQ>? NX;4eGNXW0GQR1XS
NCI-H1355 NGn2[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwM{ixJI5O MX3TRW5ITVJ?
YKG-1 NWewOXB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwNEG5JI5O Mm[3V2FPT0WU
RS4-11 NFfZe5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXjdXhKSzVyPUCuOFM{KG6P M2f6[nNCVkeHUh?=
Daoy Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwNEW2JI5O MXjTRW5ITVJ?
A3-KAW NU[wdnQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\6TWM2OD1yLkW1NUBvVQ>? MX7TRW5ITVJ?
SK-MEL-30 M17yTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NES0XGxKSzVyPUCuOVU1KG6P NUHJ[49iW0GQR1XS
U031 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLITWM2OD1yLkW2OUBvVQ>? M3jWVnNCVkeHUh?=
SK-LMS-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHCTWM2OD1yLkW3PEBvVQ>? Mn;EV2FPT0WU
ES6 M1S2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\uNFdKSzVyPUCuOVg3KG6P M3LPUXNCVkeHUh?=
EoL-1-cell MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXlTWM2OD1yLk[xOkBvVQ>? NFS0bXNUSU6JRWK=
NCI-H2009 NXO4bXVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrqV5pTUUN3ME2wMlYyQSCwTR?= MoTJV2FPT0WU
A4-Fuk MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjyZoMzUUN3ME2wMlYzPiCwTR?= NVnvNoFLW0GQR1XS
KYSE-270 NHK4cFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;0WmQ1UUN3ME2wMlY{PCCwTR?= NFq0S3ZUSU6JRWK=
SK-LU-1 NGTyfoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PXS2lEPTB;MD62OVUhdk1? NXvw[FdRW0GQR1XS
SW872 Mlr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkH3TWM2OD1yLke2OUBvVQ>? MVvTRW5ITVJ?
ES8 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGC3VoJKSzVyPUCuO|ghdk1? NGH6NHRUSU6JRWK=
G-402 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rzb2lEPTB;MD63PFQhdk1? NEPIU5BUSU6JRWK=
ATN-1 M3TnZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwOEC3JI5O M1nafnNCVkeHUh?=
DoTc2-4510 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zIXGlEPTB;MD65NFEhdk1? M4nwNHNCVkeHUh?=
MES-SA MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDVfoJKSzVyPUCuPVA2KG6P MWLTRW5ITVJ?
SF268 M2W4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwOUK3JI5O NFi4ZmdUSU6JRWK=
SF539 NGnid3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWqwWmZuUUN3ME2xMlAzKG6P NHXtb2tUSU6JRWK=
NB69 NHTaZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn64TWM2OD1zLkC1JI5O M2XaOXNCVkeHUh?=
8505C MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jUNWlEPTB;MT6wOkBvVQ>? MknNV2FPT0WU
CAL-12T M2TRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFwMEigcm0> MlLaV2FPT0WU
BHY MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnCOoJCUUN3ME2xMlE1KG6P MXvTRW5ITVJ?
LB647-SCLC MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTGN2hKSzVyPUGuNVghdk1? MXzTRW5ITVJ?
CAL-62 M{XlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jKdWlEPTB;MT6yNkBvVQ>? NE\FToVUSU6JRWK=
MEG-01 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrMZ2ZKSzVyPUGuNlchdk1? MWHTRW5ITVJ?
MG-63 M2jkdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnISGZKSzVyPUGuN|Mhdk1? M2DJTXNCVkeHUh?=
SW620 MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLhTWM2OD1zLkO1JI5O NEW3S4FUSU6JRWK=
A388 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{H1U2lEPTB;MT6zOkBvVQ>? MYfTRW5ITVJ?
BCPAP MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXJS5lKSzVyPUGuOFUhdk1? NIn6UVNUSU6JRWK=
P30-OHK MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHqyOmVKSzVyPUGuOFYhdk1? NGLNWopUSU6JRWK=
Ca9-22 NXXUelNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnZTWM2OD1zLkW0JI5O NULae21LW0GQR1XS
VMRC-RCZ Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHoW2RKSzVyPUGuOVQhdk1? Mk\UV2FPT0WU
LOXIMVI M3G3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\OUmlEPTB;MT62JI5O NYHlWpRKW0GQR1XS
L-540 M1mzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFwNjDuUS=> NEnmbHNUSU6JRWK=
NTERA-S-cl-D1 NYjkd21FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe1XVk2UUN3ME2xMlY1KG6P M4fpNnNCVkeHUh?=
MFH-ino MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH30ZmJKSzVyPUGuOlYhdk1? MnjpV2FPT0WU
Calu-6 NWjmcWNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFwN{Ogcm0> NF\Te4JUSU6JRWK=
HEL Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjSZm9lUUN3ME2xMlc6KG6P MVfTRW5ITVJ?
CAL-33 M2jCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3f5TmlEPTB;MT64PUBvVQ>? NULTfmZ3W0GQR1XS
HSC-3 MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7VTIlKSzVyPUGuPVEhdk1? NGf0fYFUSU6JRWK=
KU812 M3:0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFwOUGgcm0> M4fMenNCVkeHUh?=
EB2 M2i1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDGbI5KSzVyPUKuNFEhdk1? M1zhXXNCVkeHUh?=
SR NEfT[lJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJwMUKgcm0> MojFV2FPT0WU
NCI-H2087 NWDVSlJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHBTWM2OD1{LkG0JI5O NFG4eYFUSU6JRWK=
H4 MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn71TWM2OD1{LkG4JI5O MonYV2FPT0WU
EW-1 M1zGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULiR2FMUUN3ME2yMlIzKG6P M3\NV3NCVkeHUh?=
MC-IXC M2jMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHsbIhKSzVyPUKuNlYhdk1? NWjtRWpYW0GQR1XS
NCI-H727 MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XJSWlEPTB;Mj61NUBvVQ>? M3zRXXNCVkeHUh?=
MRK-nu-1 NHHtb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFOyfFdKSzVyPUKuOVchdk1? NF\uVHpUSU6JRWK=
COLO-668 NHPiXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJwNk[gcm0> NUfsbZZWW0GQR1XS
CGTH-W-1 NUmxUnVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rX[WlEPTB;Mj63NkBvVQ>? MXPTRW5ITVJ?
CHP-212 M1jMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJwN{Wgcm0> MnvRV2FPT0WU
GI-1 M3HhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTJwN{[gcm0> M4rpWXNCVkeHUh?=
HCC1806 NGL0OHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDNTWM2OD1{LkmxJI5O MoXKV2FPT0WU
HLE M3yzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTNibl2= MVXTRW5ITVJ?
HSC-2 NV:yXFJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLOSFNvUUN3ME2zMlA{KG6P M3TNe3NCVkeHUh?=
DMS-273 NHH4cYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTaTWM2OD1|LkC3JI5O NX7BeGpVW0GQR1XS
DU-4475 Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPETWM2OD1|LkG0JI5O M{S5RnNCVkeHUh?=
LXF-289 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXUTWM2OD1|LkOxJI5O M1XS[XNCVkeHUh?=
PANC-03-27 NIXLUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXBSVg2UUN3ME2zMlUyKG6P Mn;rV2FPT0WU
GAMG M4TJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnuxTWM2OD1|Lke0JI5O Ml7SV2FPT0WU
NCI-H522 NV;X[HhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL2SVQzUUN3ME20MlM1KG6P M1PJfHNCVkeHUh?=
SW626 MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjoTWM2OD12LkS2JI5O NXvFSXNYW0GQR1XS
HT-144 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrFT2tKSzVyPUSuPVIhdk1? MWLTRW5ITVJ?
MEL-HO NWPNXFhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHZUGNKSzVyPUWuNVYhdk1? NFLxNJVUSU6JRWK=
BE-13 M1[xeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Po[2lEPTB;NT6yNUBvVQ>? M4fkbnNCVkeHUh?=
VA-ES-BJ NG\3fmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PT[GlEPTB;NT6yOkBvVQ>? MVfTRW5ITVJ?
NCI-H441 NUXY[4JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnpbXhKSzVyPUWuOkBvVQ>? NXrXUIsxW0GQR1XS
KP-4 NWnHWnViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXVTWM2OD13Lk[xJI5O NV:2cm5kW0GQR1XS
LoVo MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT6TWM2OD13LkexJI5O NYPObmxlW0GQR1XS
HT-1080 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS5elh6UUN3ME21Mlg{KG6P NGjFbnNUSU6JRWK=
GB-1 NYHXenI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\MdGJ3UUN3ME21Mlg1KG6P Mkn4V2FPT0WU
IA-LM Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HRUGlEPTB;NT65NUBvVQ>? M{nTe3NCVkeHUh?=
8-MG-BA NEXpdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTVwOUOgcm0> MnLaV2FPT0WU
SK-HEP-1 NVn1fVl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqxTWM2OD14LkG0JI5O NFvGTIJUSU6JRWK=
697 M2jqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nFUWlEPTB;Nj6yOUBvVQ>? M1vuZnNCVkeHUh?=
KYSE-450 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlviTWM2OD14LkOyJI5O NH72eohUSU6JRWK=
HCC2998 M36wbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYntdXRDUUN3ME22MlM1KG6P NHzjeWhUSU6JRWK=
HD-MY-Z M3vSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrFXVdKSzVyPU[uOlghdk1? MULTRW5ITVJ?
OS-RC-2 NEjmd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjDbJdKSzVyPU[uOlghdk1? NWjYflZOW0GQR1XS
SF126 MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLMTWM2OD15LkC1JI5O NYjsWXE3W0GQR1XS
Ca-Ski MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTdwMEmgcm0> M4\XZ3NCVkeHUh?=
NCI-H358 MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTdwMU[gcm0> NYXDSI9SW0GQR1XS
J82 NU\LcXkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPQTplKSzVyPUeuOFEhdk1? M3\oOXNCVkeHUh?=
NCI-H2342 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXZXWVKSzVyPUeuOlMhdk1? M2X1bXNCVkeHUh?=
OVCAR-8 Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTdwOTDuUS=> MUjTRW5ITVJ?
TE-8 NHPrZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1POT2lEPTB;ODDuUS=> NV2yTZhPW0GQR1XS
ETK-1 Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrTTWM2OD16LkC4JI5O MVzTRW5ITVJ?
HAL-01 Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnPTWM2OD16LkKgcm0> M4DEdHNCVkeHUh?=
KYSE-150 M4DmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P4NWlEPTB;OD60O{BvVQ>? NEnUOHVUSU6JRWK=
NCI-H810 NEjZemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W1ZWlEPTB;OD61OkBvVQ>? Mm\oV2FPT0WU
ONS-76 NGHCcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRThwNkigcm0> MmK4V2FPT0WU
NMC-G1 MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7BTWM2OD16Lke2JI5O MVLTRW5ITVJ?
C3A MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXZTWM2OD16Lki0JI5O M4jqS3NCVkeHUh?=
PA-1 MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;uPY1mUUN3ME24Mlk6KG6P MYrTRW5ITVJ?
SH-4 NF;GUpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTlwMEKgcm0> M{G4RnNCVkeHUh?=
EFO-27 M1XIWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTlwMEWgcm0> M4XPTXNCVkeHUh?=
CAPAN-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELZcXhKSzVyPUmuNlMhdk1? MkfJV2FPT0WU
DU-145 NVG5cGhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzrTWM2OD17LkK5JI5O M2\mTnNCVkeHUh?=
A101D NETrVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorHTWM2OD17LkO3JI5O MVHTRW5ITVJ?
ST486 NYi0c4tDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnZTWM2OD17LkSxJI5O NWe5VXUyW0GQR1XS
NCI-H1437 NWrmWGI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv0eVlrUUN3ME25MlQzKG6P MkiyV2FPT0WU
HGC-27 NH;YTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDlTWM2OD17Lk[gcm0> M37RXnNCVkeHUh?=
8305C NX3vZlZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTlwNkSgcm0> NEDQRYZUSU6JRWK=
OCUB-M MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFyLkCzJI5O NHjqcotUSU6JRWK=
COLO-679 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\NepZWUUN3ME2xNE4xPyCwTR?= M1ixWHNCVkeHUh?=
Detroit562 NEXqVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ThbWlEPTB;MUCuOFIhdk1? M2rzO3NCVkeHUh?=
A204 Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTFzLkG2JI5O M2fxdHNCVkeHUh?=
NCI-H1734 NY\lVmc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFzLkK5JI5O NV6yV4RRW0GQR1XS
MC-CAR NEXybVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nyfWlEPTB;MUGuOVghdk1? NHTofoNUSU6JRWK=
NCI-H2170 NV;aN4c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTuTWM2OD1zMT65O{BvVQ>? M{DUN3NCVkeHUh?=
NCI-SNU-5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTGTWM2OD1zMj6xN{BvVQ>? MYLTRW5ITVJ?
HCE-T M{fYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIP0dVVKSzVyPUGyMlQzKG6P M3rIbXNCVkeHUh?=
KYSE-180 MoLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF{LkixJI5O NYXjXnRDW0GQR1XS
C8166 MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF|LkC4JI5O MlrjV2FPT0WU
NCI-H460 NIf5T4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTCTWM2OD1zMz61OEBvVQ>? MVvTRW5ITVJ?
SNU-449 Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nhSWlEPTB;MUOuO|chdk1? MVfTRW5ITVJ?
MDA-MB-468 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7ETWM2OD1zND6xNkBvVQ>? MmTLV2FPT0WU
COR-L23 M17B[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M321UmlEPTB;MUSuNVMhdk1? MlH2V2FPT0WU
CTV-1 M{m2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn2TWM2OD1zND6xOEBvVQ>? NWK3e2JtW0GQR1XS
BL-41 MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXaNYJ6UUN3ME2xOE4{PyCwTR?= M{fFU3NCVkeHUh?=
IGR-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPoe2plUUN3ME2xOE41OiCwTR?= MXPTRW5ITVJ?
TK10 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF2LkS5JI5O MlLrV2FPT0WU
REH M2W0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHaV25KSzVyPUG0MlUyKG6P NUj0RWRHW0GQR1XS
LU-139 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\BbWlEPTB;MUSuOVkhdk1? M2H2bHNCVkeHUh?=
KP-N-YS M{LTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF2Lkm3JI5O NYPNeVV1W0GQR1XS
PANC-10-05 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\HNWlEPTB;MUWuN|ghdk1? MWnTRW5ITVJ?
HL-60 NIHTbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF3Lk[5JI5O NGjoblRUSU6JRWK=
T84 NED0ZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTF3Lkm2JI5O NUHIN|lJW0GQR1XS
RPMI-8226 NX31R4cxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XZN2lEPTB;MU[uNFIhdk1? MnfYV2FPT0WU
UM-UC-3 M3vHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUewcmNmUUN3ME2xOk4yPiCwTR?= NInseYpUSU6JRWK=
TE-10 NHPrN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfOeo9KSzVyPUG2MlIyKG6P MmLlV2FPT0WU
CAL-148 M3jOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF5LkKzJI5O NG[wfGpUSU6JRWK=
BV-173 M{DDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTF5LkK3JI5O M4jkOHNCVkeHUh?=
Calu-3 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjXd25KSzVyPUG3MlI6KG6P MXrTRW5ITVJ?
RPMI-2650 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTF5LkW5JI5O NUjtN3pTW0GQR1XS
MKN45 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlu2TWM2OD1zNz63N{BvVQ>? M{nZVXNCVkeHUh?=
NUGC-3 NGXFS|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInwfppKSzVyPUG4MlM1KG6P MmfHV2FPT0WU
NCI-H520 NEHkSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rkW2lEPTB;MUiuO|chdk1? MXrTRW5ITVJ?
CCRF-CEM MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHUT4JKSzVyPUG4Mlg2KG6P NF;rVWpUSU6JRWK=
NCI-H2405 NGf3PYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXJOWJKSzVyPUG5MlEhdk1? NInuNXpUSU6JRWK=
ES7 NUDPcldHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF7Lke2JI5O Ml73V2FPT0WU
BPH-1 NGflelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJyLkK4JI5O NWjJSXE5W0GQR1XS
SAS NHfPRZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfW[2hKSzVyPUKwMlUhdk1? Mn7vV2FPT0WU
HuCCT1 M3yxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJyLkW4JI5O NHfkRVBUSU6JRWK=
LOUCY Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW2TWM2OD1{MD62OkBvVQ>? MVrTRW5ITVJ?
NCI-H292 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G0N2lEPTB;MkCuO|khdk1? NHjRc3NUSU6JRWK=
G-361 NF\zfHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPzc3g3UUN3ME2yNU4xPyCwTR?= NHzwSGRUSU6JRWK=
M059J NWHCPFRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJzLkC4JI5O MWfTRW5ITVJ?
NCI-H1651 MkL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJzLkGxJI5O M4nuVnNCVkeHUh?=
KALS-1 NVG1VXFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO2TWM2OD1{MT6zPUBvVQ>? MYjTRW5ITVJ?
DJM-1 M3Hqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PDfWlEPTB;MkGuOVkhdk1? M{nNOXNCVkeHUh?=
AU565 MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPFTWM2OD1{MT64N{BvVQ>? MXrTRW5ITVJ?
HCC38 M3nWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zPeGlEPTB;MkGuPVUhdk1? NELMSmlUSU6JRWK=
U251 M4G5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTZdnhKSzVyPUKyMlI4KG6P NXLjUFR{W0GQR1XS
ABC-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ{Lk[1JI5O MY\TRW5ITVJ?
SK-NEP-1 M4DVdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33TO2lEPTB;MkKuPVMhdk1? MV3TRW5ITVJ?
CESS Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPNOnVXUUN3ME2yN{4yQSCwTR?= NWHOWZVyW0GQR1XS
MIA-PaCa-2 NIC3Z3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJ|LkO2JI5O Mli3V2FPT0WU
SUP-T1 NUHOZ2FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJ|LkS3JI5O MoTYV2FPT0WU
L-428 NWDqR|NDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PpeGlEPTB;MkOuOlIhdk1? M32yVXNCVkeHUh?=
SW954 MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJ|Lk[4JI5O MVPTRW5ITVJ?
HO-1-N-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXNTWM2OD1{Mz63O{BvVQ>? M4\iZXNCVkeHUh?=
CHP-126 NVrqWVlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJ2LkG0JI5O Mnn0V2FPT0WU
HMV-II NYjvb2Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHmTWM2OD1{ND6zOEBvVQ>? M{T3UXNCVkeHUh?=
NB10 NWX5co43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPiPZRYUUN3ME2yOE4{PyCwTR?= NIXLSIFUSU6JRWK=
A172 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJ2LkexJI5O MoDEV2FPT0WU
MONO-MAC-6 MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrJTWM2OD1{ND64OEBvVQ>? M4rqTXNCVkeHUh?=
NCI-H1650 NHqwcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFiyU|JKSzVyPUK1MlQhdk1? MofZV2FPT0WU
NH-12 M4S2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfteWxKSzVyPUK1MlUhdk1? M1vxPXNCVkeHUh?=
ML-2 NXfodmJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnGN3lKUUN3ME2yOU44PCCwTR?= M3KwcXNCVkeHUh?=
MZ2-MEL MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJ4LkKyJI5O MVHTRW5ITVJ?
COLO-684 Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG5U2ltUUN3ME2yOk41OSCwTR?= M1m0[nNCVkeHUh?=
HuP-T4 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LtdWlEPTB;MkeuN{BvVQ>? M1jtS3NCVkeHUh?=
SW837 NYnCN2NyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjVZYZKSzVyPUK3MlYzKG6P MYXTRW5ITVJ?
MDA-MB-231 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL3RYRXUUN3ME2yO{44QCCwTR?= MYnTRW5ITVJ?
KYSE-140 NYjIVmdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTnTWM2OD1{Nz65NUBvVQ>? M3XqfnNCVkeHUh?=
NOMO-1 NV;wWmQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJ6Lk[4JI5O M4XsSnNCVkeHUh?=
GP5d MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjBNnFKSzVyPUK4MlczKG6P NIruNGVUSU6JRWK=
COR-L105 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7GZmxKSzVyPUK5MlQzKG6P MV;TRW5ITVJ?
LS-411N NXn6dW5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJ7Lki4JI5O MXrTRW5ITVJ?
NY M2X5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjXdHlKSzVyPUOwMlE5KG6P NFvXUpdUSU6JRWK=
NCI-H2030 NH3teXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHS4eW9KSzVyPUOwMlQ2KG6P NHPFVHZUSU6JRWK=
CCF-STTG1 NGrvV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnQTWM2OD1|MT60NkBvVQ>? MlfhV2FPT0WU
NCI-H1703 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLpTWM2OD1|MT63PEBvVQ>? MojMV2FPT0WU
TUR M17BPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV2xSnNwUUN3ME2zNk4xOyCwTR?= M3zlPXNCVkeHUh?=
NOS-1 M{TWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTN{LkS0JI5O NEG3dpZUSU6JRWK=
A2058 NUD4NoFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILo[FBKSzVyPUOyMlg{KG6P M1Pod3NCVkeHUh?=
LCLC-103H MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\WTWM2OD1|Mz6yOUBvVQ>? NFX0RWRUSU6JRWK=
NCI-H510A M4\nZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHGVoxKSzVyPUOzMlI4KG6P Mo\NV2FPT0WU
BC-1 NEXIdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe5ZnJ{UUN3ME2zN{44PyCwTR?= MYPTRW5ITVJ?
SK-CO-1 Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTVW|ZJUUN3ME2zOE4xOSCwTR?= MX\TRW5ITVJ?
A673 NIe3cJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\ZdmlEPTB;M{SuNVchdk1? NGS2T5RUSU6JRWK=
VM-CUB-1 MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\QT5dKSzVyPUO0MlY6KG6P NWLmXYNJW0GQR1XS
HH MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGCxUYJKSzVyPUO1MlA3KG6P NIC2RZZUSU6JRWK=
CAL-27 NXniTpY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHBdVdKSzVyPUO1MlE3KG6P NEH6TpRUSU6JRWK=
NEC8 Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PT[WlEPTB;M{WuN|chdk1? MmPYV2FPT0WU
BxPC-3 NV;wZXFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi0cnZQUUN3ME2zOk46OSCwTR?= NVLGSpRUW0GQR1XS
SNB75 NYTp[lBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLqdGVNUUN3ME2zO{4zPCCwTR?= MVvTRW5ITVJ?
NB13 NYrTUnZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7D[VBWUUN3ME2zPE4zOyCwTR?= M3zr[XNCVkeHUh?=
SK-OV-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfBPFFKSzVyPUO4Mlc1KG6P NHHmfpRUSU6JRWK=
ME-180 NFLqb4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT0dmZKSzVyPUO4Mlghdk1? NUTuOphIW0GQR1XS
JiyoyeP-2003 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHTTWM2OD1|OT6zPEBvVQ>? NV7URYVWW0GQR1XS
LU-134-A NGrxXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XIW2lEPTB;NECuNFIhdk1? NYWwW4FZW0GQR1XS
LS-123 NF\U[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO4RmVGUUN3ME20NE4zQCCwTR?= MnrzV2FPT0WU
COLO-800 NGPkd4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnFTWM2OD12MD61OkBvVQ>? MmLGV2FPT0WU
LB831-BLC MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTRzLki1JI5O NF7ae3FUSU6JRWK=
NCI-H747 M2rPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfkZopKSzVyPUSyMlI5KG6P MlHXV2FPT0WU
MZ7-mel NV;hW4t2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTR{Lk[2JI5O MWDTRW5ITVJ?
GT3TKB NWrHOY1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXyS4dmUUN3ME20Nk44OiCwTR?= MUfTRW5ITVJ?
MOLT-16 NHL2NWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTR|LkC1JI5O NV;QZppHW0GQR1XS
23132-87 MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LSfmlEPTB;NEOuNFUhdk1? Mn3vV2FPT0WU
PF-382 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnxb3VKSzVyPUS0MlIzKG6P NHraU2tUSU6JRWK=
ES3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTR2Lk[gcm0> MUTTRW5ITVJ?
SW756 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS1[JJKSzVyPUS1MlE1KG6P MWjTRW5ITVJ?

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい
体内試験 Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

お薦めの試験操作（参考用のみ）

溶解度 (25°C)

体外 DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
体内 左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
water (warmed)
混合させたのち直ちに使用することを推奨します。 		52mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 263.2
化学式

C9H11F2N3O4
CAS No. 95058-81-4
保管 粉
in solvent
別名 LY-188011, NSC 613327

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

総分子量：g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03739619 Not yet recruiting Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Classical Hodgkin Lymphoma|Hodgkin Lymphoma Emory University|Bristol-Myers Squibb November 1 2019 Phase 1|Phase 2
NCT03541486 Not yet recruiting Pancreatic Neoplasm Joseph J. Cullen|Holden Comprehensive Cancer Center|University of Iowa April 1 2019 Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic April 1 2019 Phase 1|Phase 2
NCT03669601 Not yet recruiting Cancer CCTU- Cancer Theme|AstraZeneca|Cambridge University Hospitals NHS Foundation Trust March 31 2019 Phase 1
NCT03690739 Not yet recruiting Recurrent Ovarian Carcinoma AGO Research GmbH February 1 2019 Phase 3
NCT03085004 Not yet recruiting Pancreatic Cyst|EUS-FNA Milton S. Hershey Medical Center January 2019 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問（FAQ）

  • 質問1：

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • 回答：

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

selleck catalog

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

  • SCR7

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

  • YK-4-279

    YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).

  • BMH-21

    BMH-21 is a DNA intercalator, which binds ribosomal DNA and inhibits RNA polymerase I (Pol I) transcription.

  • Cisplatin

    Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells.

    Features:One of the most widely used and most potent chemotherapeutic agents.

  • Gemcitabine HCl

    Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

    Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.

  • Bleomycin Sulfate

    Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

  • Fluorouracil (5-Fluoracil, 5-FU)

    Fluorouracil (5-Fluoracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.

Tags: Gemcitabine を買う | Gemcitabine ic50 | Gemcitabine 供給者 | Gemcitabine を購入する | Gemcitabine 費用 | Gemcitabine 生産者 | オーダーGemcitabine | Gemcitabine 化学構造 | Gemcitabine 分子量 | Gemcitabine 代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID